| 000 | 01114 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250516172439.0 | ||
| 264 | 0 | _c20140108 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1474-4457 | ||
| 024 | 7 |
_a10.1016/S1473-3099(13)70194-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBoyd, Mark A | |
| 245 | 0 | 0 |
_aSPRING-2 the future of antiretroviral therapy. _h[electronic resource] |
| 260 |
_bThe Lancet. Infectious diseases _cNov 2013 |
||
| 300 |
_a908-9 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Integrase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHIV-1 _xisolation & purification |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOxazines |
| 650 | 0 | 4 | _aPiperazines |
| 650 | 0 | 4 | _aPyridones |
| 700 | 1 | _aCooper, David A | |
| 773 | 0 |
_tThe Lancet. Infectious diseases _gvol. 13 _gno. 11 _gp. 908-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1473-3099(13)70194-4 _zAvailable from publisher's website |
| 999 |
_c23124735 _d23124735 |
||